{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:07:56Z","timestamp":1778746076106,"version":"3.51.4"},"reference-count":65,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0225572","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T18:32:07Z","timestamp":1575484327000},"page":"e0225572","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9766-5196","authenticated-orcid":true,"given":"Raymond K.","family":"Cross","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Chiorean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Vekeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingdong","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7551-4730","authenticated-orcid":true,"given":"Anthony W.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"issue":"12","key":"pone.0225572.ref001","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/apt.12749","article-title":"Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease","volume":"39","author":"RW Stidham","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"pone.0225572.ref002","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/apt.12644","article-title":"Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis","volume":"39","author":"RW Stidham","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"pone.0225572.ref003","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.trsl.2014.01.002","article-title":"Biologic therapies in inflammatory bowel disease","volume":"163","author":"LB Cohen","year":"2014","journal-title":"Translational research: the journal of laboratory and clinical medicine"},{"issue":"1","key":"pone.0225572.ref004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management","volume":"11","author":"F Gomollon","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"2","key":"pone.0225572.ref005","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohn's disease in adults","volume":"104","author":"GR Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"pone.0225572.ref006","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/11586290-000000000-00000","article-title":"Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies","volume":"24","author":"F Magro","year":"2010","journal-title":"BioDrugs"},{"key":"pone.0225572.ref007","unstructured":"Janssen Biotech I. SIMPONI (golimumab) prescribing information 2013 [cited 2017 March 2]. 1\u201333]. Available from: http:\/\/www.simponi.com\/shared\/product\/simponi\/prescribing-information.pdf."},{"issue":"4","key":"pone.0225572.ref008","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","article-title":"TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants\u2014past, present and future","volume":"25","author":"LM Sedger","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"pone.0225572.ref009","doi-asserted-by":"crossref","first-page":"493012","DOI":"10.1155\/2015\/493012","article-title":"Inflammatory bowel disease: an overview of immune mechanisms and biological treatments","volume":"2015","author":"BR de Mattos","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"9","key":"pone.0225572.ref010","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2217\/imt.12.85","article-title":"Vedolizumab for the treatment of ulcerative colitis and Crohn's disease","volume":"4","author":"LP McLean","year":"2012","journal-title":"Immunotherapy"},{"issue":"1","key":"pone.0225572.ref011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2613.2003.00235.x","article-title":"Role of cell adhesion molecules in leukocyte recruitment in the liver and gut","volume":"84","author":"A Ala","year":"2003","journal-title":"Int J Exp Pathol"},{"issue":"10","key":"pone.0225572.ref012","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management","volume":"6","author":"A Dignass","year":"2012","journal-title":"J Crohns Colitis"},{"issue":"1","key":"pone.0225572.ref013","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management","volume":"4","author":"A Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"issue":"6","key":"pone.0225572.ref014","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1053\/j.gastro.2013.10.047","article-title":"American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease","volume":"145","author":"JP Terdiman","year":"2013","journal-title":"Gastroenterology"},{"issue":"8","key":"pone.0225572.ref015","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00228-011-1079-3","article-title":"A meta-analysis of the therapeutic effects of tumor necrosis factor-alpha blockers on ulcerative colitis","volume":"67","author":"X Huang","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"126","key":"pone.0225572.ref016","first-page":"1333","article-title":"Meta-analysis: serious adverse events in Crohn's disease patients treated with TNF-alpha inhibitors","volume":"60","author":"D Zhang","year":"2013","journal-title":"Hepatogastroenterology"},{"key":"pone.0225572.ref017","first-page":"1","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"3","author":"JA Singh","year":"2012","journal-title":"Cochrane Database of Syst Rev"},{"issue":"8","key":"pone.0225572.ref018","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/ajg.2015.205","article-title":"Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience","volume":"110","author":"E Freling","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"pone.0225572.ref019","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2036.2008.03882.x","article-title":"The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up","volume":"29","author":"CW Lees","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"pone.0225572.ref020","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry","volume":"107","author":"GR Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"pone.0225572.ref021","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease","volume":"104","author":"J Marehbian","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"pone.0225572.ref022","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"BG Feagan","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0225572.ref023","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"WJ Sandborn","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0225572.ref024","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/apt.13594","article-title":"Vedolizumab induction therapy for inflammatory bowel disease in clinical practice\u2014a nationwide consecutive German cohort study","volume":"43","author":"DC Baumgart","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"pone.0225572.ref025","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","article-title":"Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease","volume":"14","author":"A Amiot","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"pone.0225572.ref026","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/ecco-jcc\/jjv226","article-title":"Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice","volume":"10","author":"EE Vivio","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"12","key":"pone.0225572.ref027","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1097\/MIB.0000000000000561","article-title":"Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort","volume":"21","author":"E Shelton","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"pone.0225572.ref028","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: results from the US VICTORY Consortium","volume":"111","author":"PS Dulai","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"pone.0225572.ref029","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.2013.725","article-title":"Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence","volume":"110","author":"CM Booth","year":"2014","journal-title":"Br J Cancer"},{"issue":"6","key":"pone.0225572.ref030","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2310\/JIM.0b013e3181e3d2af","article-title":"Comparative effectiveness research: what kind of studies do we need?","volume":"58","author":"J Concato","year":"2010","journal-title":"J Investig Med"},{"issue":"34","key":"pone.0225572.ref031","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.2012.42.2659","article-title":"Methods in comparative effectiveness research","volume":"30","author":"K. Armstrong","year":"2012","journal-title":"J Clin Oncol"},{"key":"pone.0225572.ref032","author":"KJ Rothman","year":"2008"},{"issue":"2","key":"pone.0225572.ref033","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2009.25.8608","article-title":"Generalizing the results of cancer clinical trials","volume":"28","author":"RM Meyer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0225572.ref034","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2105-15-17","article-title":"Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection","volume":"15","author":"R Xu","year":"2014","journal-title":"BMC bioinformatics"},{"issue":"2","key":"pone.0225572.ref035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/11319000-000000000-00000","article-title":"Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles","volume":"33","author":"S Bailey","year":"2010","journal-title":"Drug Saf"},{"issue":"1","key":"pone.0225572.ref036","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1208\/s12248-007-9004-5","article-title":"Informatic tools and approaches in postmarketing pharmacovigilance used by FDA","volume":"10","author":"J Weaver","year":"2008","journal-title":"The AAPS journal"},{"issue":"7","key":"pone.0225572.ref037","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"T Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"10","key":"pone.0225572.ref038","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2165\/00002018-200629100-00005","article-title":"Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department","volume":"29","author":"JS Almenoff","year":"2006","journal-title":"Drug safety"},{"issue":"3","key":"pone.0225572.ref039","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1742-7843.2006.pto_232.x","article-title":"Data mining in spontaneous reports","volume":"98","author":"A Bate","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"pone.0225572.ref040","unstructured":"Center for Drug Evaluation and Research, U. S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Silver Spring, MD: U.S. Food and Drug Administration; 2015 [cited 2016 February 19, 2016]. Available from: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/."},{"key":"pone.0225572.ref041","article-title":"MedDRA\u2013Beyond that basic AE report","author":"P. Giese","year":"2013","journal-title":"How SMQs and MedDRA structure can enhance reporting"},{"key":"pone.0225572.ref042","unstructured":"Office of the Commissioner, U. S. Food and Drug Administration. Reporting serious problems to the FDA\u2014What is a serious adverse event? Silver Spring, MD: U.S. Food and Drug Administration; 2016 [cited 2016 February 19, 2016]. Available from: http:\/\/www.fda.gov\/Safety\/MedWatch\/HowToReport\/ucm053087.htm."},{"issue":"6","key":"pone.0225572.ref043","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archinternmed.2011.89","article-title":"The FDA drug safety surveillance program: adverse event reporting trends","volume":"171","author":"S Weiss-Smith","year":"2011","journal-title":"Arch Intern Med"},{"issue":"11","key":"pone.0225572.ref044","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s40264-013-0115-x","article-title":"Adverse event reporting patterns of newly approved drugs in the USA in 2006: an analysis of FDA Adverse Event Reporting System data","volume":"36","author":"P Chhabra","year":"2013","journal-title":"Drug safety"},{"issue":"12","key":"pone.0225572.ref045","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/pds.4090","article-title":"Can social media data lead to earlier detection of drug-related adverse events?","volume":"25","author":"MS Duh","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0225572.ref046","author":"HJ Duggirala","year":"2015"},{"issue":"1","key":"pone.0225572.ref047","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF03256796","article-title":"Data Mining in drug safety","volume":"24","author":"G Deshpande","year":"2010","journal-title":"Pharmaceutical Medicine"},{"key":"pone.0225572.ref048","author":"R Core Team","year":"2014"},{"key":"pone.0225572.ref049","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","author":"JF Colombel","year":"2016","journal-title":"Gut"},{"issue":"28","key":"pone.0225572.ref050","first-page":"e326","article-title":"PRISMA\u2014efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials","volume":"93","author":"MC Wang","year":"2014","journal-title":"MedicinePubMed Central PMCID"},{"issue":"12","key":"pone.0225572.ref051","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/apt.13215","article-title":"Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease","volume":"41","author":"P Luthra","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"pone.0225572.ref052","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration","volume":"46","author":"SL Brown","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"8","key":"pone.0225572.ref053","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","article-title":"Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration","volume":"62","author":"P Diak","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"pone.0225572.ref054","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/ajg.2012.334","article-title":"T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study","volume":"108","author":"P Deepak","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"pone.0225572.ref055","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3899\/jrheum.080545","article-title":"A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database","volume":"36","author":"JD Carter","year":"2009","journal-title":"J Rheumatol"},{"issue":"33","key":"pone.0225572.ref056","doi-asserted-by":"crossref","first-page":"9688","DOI":"10.3748\/wjg.v21.i33.9688","article-title":"Cardiovascular involvement in inflammatory bowel disease: dangerous liaisons","volume":"21","author":"AM Filimon","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"6","key":"pone.0225572.ref057","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.crohns.2013.09.021","article-title":"Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies","volume":"8","author":"M Fumery","year":"2014","journal-title":"J Crohns Colitis"},{"issue":"3","key":"pone.0225572.ref058","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cgh.2013.08.023","article-title":"Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"12","author":"S Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"pone.0225572.ref059","first-page":"115","article-title":"Crohn's disease and ulcerative colitis: an echocardiographic case-control study","volume":"58","author":"E Vizzardi","year":"2016","journal-title":"Panminerva medica"},{"issue":"7","key":"pone.0225572.ref060","doi-asserted-by":"crossref","first-page":"11324","DOI":"10.3390\/ijms150711324","article-title":"Endothelial dysfunction in chronic inflammatory diseases","volume":"15","author":"CM 3rd Steyers","year":"2014","journal-title":"International journal of molecular sciences"},{"issue":"2","key":"pone.0225572.ref061","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000116773","article-title":"Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects","volume":"26","author":"A Papa","year":"2008","journal-title":"Dig Dis"},{"issue":"3","key":"pone.0225572.ref062","first-page":"269","article-title":"Infectious complications of TNF-alpha inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System","volume":"22","author":"P Deepak","year":"2013","journal-title":"J Gastrointestin Liver Dis"},{"issue":"6","key":"pone.0225572.ref063","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1097\/MIB.0b013e31828075bd","article-title":"Tumor necrosis factor alpha antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system","volume":"19","author":"KE Kip","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"pone.0225572.ref064","doi-asserted-by":"crossref","first-page":"267","DOI":"10.15403\/jgld.2014.1121.233.mrmk","article-title":"Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-alpha inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System","volume":"23","author":"MR McKenna","year":"2014","journal-title":"J Gastrointestin Liver Dis"},{"issue":"4","key":"pone.0225572.ref065","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/apt.12385","article-title":"Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System","volume":"38","author":"P Deepak","year":"2013","journal-title":"Aliment Pharmacol Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0225572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T09:36:36Z","timestamp":1612949796000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0225572"}},"subtitle":[],"editor":[{"given":"Jingjing","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,4]]},"references-count":65,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0225572","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,4]]}}}